Genmab AS (GEN) - Financial and Strategic SWOT Analysis Review

  • ID: 1291999
  • SWOT Analysis
  • 52 pages
  • GlobalData
  • Genmab AS
1 of 5

FEATURED COMPANIES

  • Bavarian Nordic A/S
  • Biogen Inc
  • Dansk Biotek
  • Genentech Inc
  • NeuroSearch A/S
  • MORE
Genmab AS (GEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analysts summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Genmab A/S (Genmab) is a biotechnology company that develops differentiated human antibody therapeutics for the treatment of cancer. The company's marketed antibody, ofatumumab (Arzerra) and Daratumumab (Darzalex) are indicated for the treatment of chronic lymphocytic leukemia and multiple myeloma respectively. Genmab’s products are based on three next generation antibody technologies, namely, HexaBody, DuoBody, and antibody drug conjugate (ADC) technologies. The company works in partnership with various pharmaceutical and biotechnology companies for the co-development and commercialization of antibody-based products. It operates in Denmark, the Netherlands, and the US. Genmab is headquartered in Copenhagen, Denmark.

Genmab AS Key Recent Developments

Jul 17, 2018: Genmab Announces Net Sales of DARZALEX (daratumumab) for Second Quarter of 2018
Jul 16, 2018: Genmab and Immatics to develop bispecific cancer therapies
May 08, 2018: Genmab: Interim Report First Quarter 2018
Feb 21, 2018: Genmab 2017 Annual Report
Dec 11, 2017: Genmab’s 2017 R&D Update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bavarian Nordic A/S
  • Biogen Inc
  • Dansk Biotek
  • Genentech Inc
  • NeuroSearch A/S
  • MORE
Section 1 - About the Company
  • Genmab A/S - Key Facts
  • Genmab A/S - Key Employees
  • Genmab A/S - Key Employee Biographies
  • Genmab A/S - Major Products and Services
  • Genmab A/S - History
  • Genmab A/S - Company Statement
  • Genmab A/S - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 – Company Analysis
  • Company Overview
  • Genmab A/S - Business Description
  • R&D Overview
  • Genmab A/S - SWOT Analysis
  • SWOT Analysis - Overview
  • Genmab A/S - Strengths
  • Genmab A/S - Weaknesses
  • Genmab A/S - Opportunities
  • Genmab A/S - Threats
  • Genmab A/S - Key Competitors
Section 3 – Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
  • Genmab A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Genmab A/S, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Genmab A/S, Recent Deals Summary
Section 5 – Company’s Recent Developments
  • Jul 17, 2018: Genmab Announces Net Sales of DARZALEX (daratumumab) for Second Quarter of 2018
  • Jul 16, 2018: Genmab and Immatics to develop bispecific cancer therapies
  • Jul 16, 2018: Genmab and Immatics to develop bispecific cancer therapies
  • May 08, 2018: Genmab: Interim Report First Quarter 2018
  • Feb 21, 2018: Genmab 2017 Annual Report
  • Dec 11, 2017: Genmab’s 2017 R&D Update
  • Dec 04, 2017: Genmab to Hold 2017 R&D Update
  • Nov 08, 2017: Genmab Announces Financial Results for the First Nine Months of 2017
  • Aug 09, 2017: Genmab Announces Financial Results for the First Half of 2017
  • May 10, 2017: Genmab Announces Financial Results for the First Quarter of 2017
Section 6 – Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • Genmab A/S, Key Facts
  • Genmab A/S, Key Employees
  • Genmab A/S, Key Employee Biographies
  • Genmab A/S, Major Products and Services
  • Genmab A/S, History
  • Genmab A/S, Subsidiaries
  • Genmab A/S, Key Competitors
  • Genmab A/S, Ratios based on current share price
  • Genmab A/S, Annual Ratios
  • Genmab A/S, Annual Ratios
  • Genmab A/S, Interim Ratios
  • Genmab A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Genmab A/S, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Genmab A/S, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Genmab A/S, Performance Chart (2013 - 2017)
  • Genmab A/S, Ratio Charts
  • Genmab A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Genmab A/S, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Teva Pharmaceutical Industries Ltd
  • NeuroSearch A/S
  • Medical Prognosis Institute A/S
  • Genentech Inc
  • Dansk Biotek
  • Biogen Inc
  • Bavarian Nordic A/S
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll